S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
NASDAQ:ELYM

Eliem Therapeutics (ELYM) Stock Price, News & Analysis

$2.79
+0.03 (+1.09%)
(As of 02:14 PM ET)
Today's Range
$2.72
$2.80
50-Day Range
$2.54
$2.97
52-Week Range
$2.34
$3.72
Volume
2,377 shs
Average Volume
5,903 shs
Market Capitalization
$76.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ELYM stock logo

About Eliem Therapeutics Stock (NASDAQ:ELYM)

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

ELYM Stock Price History

ELYM Stock News Headlines

Checkpoint Therapeutics Inc CKPT
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Eliem Therapeutics Inc ELYM
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
Eliem Therapeutics GAAP EPS of -$0.84
SVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)
ELYM Eliem Therapeutics, Inc.
Eliem Therapeutics slashing staff amid leadership shakeup
See More Headlines
Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ELYM
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-45,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.84 per share

Miscellaneous

Free Float
26,277,000
Market Cap
$76.09 million
Optionable
Not Optionable
Beta
0.50
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Andrew Levin M.D. (Age 46)
    Ph.D., Principal Financial Officer & Executive Chairman
    Comp: $73k
  • Dr. Valerie Morisset Ph.D. (Age 54)
    Chief Scientific Officer and Executive VP of Research & Development
    Comp: $617.87k
  • Ms. Emily Pimblett (Age 40)
    Principal Accounting Officer
  • Ms. Jo Palmer-Phillips Ph.D.
    Chief Development Officer

ELYM Stock Analysis - Frequently Asked Questions

How have ELYM shares performed in 2024?

Eliem Therapeutics' stock was trading at $2.70 at the beginning of 2024. Since then, ELYM stock has increased by 3.3% and is now trading at $2.79.
View the best growth stocks for 2024 here
.

Are investors shorting Eliem Therapeutics?

Eliem Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 13,000 shares, an increase of 19.3% from the February 29th total of 10,900 shares. Based on an average daily volume of 6,800 shares, the days-to-cover ratio is currently 1.9 days. Approximately 0.1% of the company's stock are sold short.
View Eliem Therapeutics' Short Interest
.

When is Eliem Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our ELYM earnings forecast
.

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.19.

When did Eliem Therapeutics IPO?

Eliem Therapeutics (ELYM) raised $75 million in an initial public offering on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Who are Eliem Therapeutics' major shareholders?

Eliem Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BML Capital Management LLC (7.91%), Northern Trust Corp (0.18%) and Cerity Partners LLC (0.05%).

How do I buy shares of Eliem Therapeutics?

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELYM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners